Myelofibrosis clinical trials

Explore recruiting myelofibrosis clinical trials.

Recruiting myelofibrosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myelofibrosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase 2, randomized, open-label, multicenter study to evaluate safety and efficacy of single agent selinexor versus treatment of physician’s choice in patients with previously treated myelofibrosis.

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination with an Approved JAK inhibitor in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED)

Spain, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS

France, Spain, Czechia, Italy, Bulgaria, Romania +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

HOVON 172 MF: A phase 1b/2 trial with tasquinimod in patients with myelofibrosis (primary, post-PV or post-ET) refractory to or intolerant for JAK2 inhibition: the TasqForce trial

Germany, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive

Belgium, Germany, Austria, Poland, Spain, Italy +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Myelofibrosis trials by city

Myelofibrosis in Toronto Myelofibrosis in Vancouver Myelofibrosis in Montreal Myelofibrosis in Calgary Myelofibrosis in Edmonton Myelofibrosis in Ottawa Myelofibrosis in Winnipeg Myelofibrosis in Quebec City Myelofibrosis in Hamilton Myelofibrosis in Kitchener Myelofibrosis in London Myelofibrosis in Halifax Myelofibrosis in New York Myelofibrosis in Los Angeles Myelofibrosis in Chicago Myelofibrosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease